论文部分内容阅读
贝林格尔·曼海姆公司停止开发匹莫苯坦治疗心力衰竭的药物匹莫苯坦（ｐｉｍｏｂｅｎ－ｄａｎ）的临床试验结果提示，该药可能与增加死亡危险有关，因而贝林格尔·曼海姆公司（Ｂｏｅｈｒｉｎｇｅｒｌｎｇｅｌｈｅｉｍ）已再一次停止这一药物的开发。ＰＩＣＯ（ｐｉｍｏｂ...
The results of a clinical trial of pimoben-dan, a drug that has failed to develop pimobendan in the treatment of heart failure, suggest that the drug may be linked to an increased risk of death, Boehringerlngelheim has once again stopped the development of this drug. PICO (pimob ...